GETI-B Stock Analysis: Getinge ser. | ST
Medical Devices | ST, Sweden | Market Cap: 62.209m SEK | 12M Return: 19.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 130M
EPS Trend: 80.5%
Qual. Beats: 1
Rev. Trend: 76.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Getinge AB (publ) is a Swedish medical technology company founded in 1904 and headquartered in Gothenburg, operating across three reporting segments: Acute Care Therapies, Life Science, and Surgical Workflows. Its product portfolio spans operating room equipment, anesthesia, intensive-care infrastructure, mechanical ventilation, extracorporeal membrane oxygenation (ECMO), intra-aortic balloon counterpulsation, surgical perfusion, and endoscopic vessel harvesting, along with sterilization, cleaning, disinfection, and sterile supply management solutions for hospitals. The Life Science segment extends these capabilities into pharmaceutical and bioprocessing applications, including terminal sterilization, aseptic transfer, bioreactor preparation, and vivarium solutions. The company distributes through direct sales subsidiaries, agents, and distributors across the Americas, Europe, the Middle East, Africa, and Asia-Pacific.
As a mid-cap constituent in the Health Care Equipment sub-industry, Getinge operates a diversified business model that combines capital medical devices, consumables, and recurring service revenue across acute hospital care and pharmaceutical production. Its dual exposure to clinical care and life sciences provides some diversification between cyclical hospital capital spending and the more regulated, longer-cycle bioprocessing market.
- Life Science segment accelerates on biopharma capex recovery
- Hospital budget tightening weighs on Surgical Workflows orders
- Acute Care Therapies margins face post-COVID ventilator normalization
| Net Income: 2.68b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 1.83 > 1.0 |
| NWC/Revenue: 10.91% < 20% (prev 8.11%; Δ 2.80% < -1%) |
| CFO/TA 0.09 > 3% & CFO 5.03b > Net Income 2.68b |
| Net Debt (10.7b) to EBITDA (6.46b): 1.65 < 3 |
| Current Ratio: 1.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (272.4m) vs 12m ago 0.0% < -2% |
| Gross Margin: 47.57% > 18% (prev 46.89%; Δ 0.68% > 0.5%) |
| Asset Turnover: 60.20% > 50% (prev 62.97%; Δ -2.77% > 0%) |
| Interest Coverage Ratio: 7.41 > 6 (EBIT TTM 4.41b / Interest Expense TTM 595.0m) |
| A: 0.07 (Total Current Assets 15.8b - Total Current Liabilities 12.0b) / Total Assets 57.4b |
| B: 0.37 (Retained Earnings 21.5b / Total Assets 57.4b) |
| C: 0.08 (EBIT TTM 4.41b / Avg Total Assets 56.9b) |
| D: 1.17 (Book Value of Equity 30.9b / Total Liabilities 26.4b) |
| Altman-Z'' = 3.40 = A |
| DSRI: 1.02 (Receivables 6.88b/7.00b, Revenue 34.2b/35.5b) |
| GMI: 0.99 (GM 46.89% / 47.57%) |
| AQI: 1.01 (AQ_t 0.64 / AQ_t-1 0.63) |
| SGI: 0.96 (Revenue 34.2b / 35.5b) |
| TATA: -0.04 (NI 2.68b - CFO 5.03b) / TA 57.4b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of July 29, 2026, the stock is trading at SEK 230.30 with a total of 530,879 shares traded. Over the past week, the price has changed by -0.73%, over one month by +16.46%, over three months by +18.47% and over the past year by +19.29%.
Current recommended Stop Loss: 221.00 (which is 4% or 1.7 ATR below the current price).
Getinge ser. has no consensus analysts rating.
P/E Trailing = 23.2114
P/E Forward = 18.622
P/S = 1.8322
P/B = 2.0165
P/EG = 1.6057
Revenue TTM = 34.2b SEK
EBIT TTM = 4.41b SEK
EBITDA TTM = 6.46b SEK
Long Term Debt = 7.94b SEK (from longTermDebt, last quarter)
Short Term Debt = 2.01b SEK (from shortTermDebt, last quarter)
Debt = 12.7b SEK (from shortLongTermDebtTotal, last quarter) + Leases 1.62b
Net Debt = 10.7b SEK (calculated: Debt 12.7b - CCE 2.05b)
Enterprise Value = 72.9b SEK (62.2b + Debt 12.7b - CCE 2.05b)
Interest Coverage Ratio = 7.41 (Ebit TTM 4.41b / Interest Expense TTM 595.0m)
EV/FCF = 19.16x (Enterprise Value 72.9b / FCF TTM 3.80b)
FCF Yield = 5.22% (FCF TTM 3.80b / Enterprise Value 72.9b)
FCF Margin = 11.11% (FCF TTM 3.80b / Revenue TTM 34.2b)
Net Margin = 7.82% (Net Income TTM 2.68b / Revenue TTM 34.2b)
Gross Margin = 47.57% ((Revenue TTM 34.2b - Cost of Revenue TTM 17.9b) / Revenue TTM)
Gross Margin QoQ = 52.69% (prev 48.45%)
Tobins Q-Ratio = 1.27 (Enterprise Value 72.9b / Total Assets 57.4b)
Interest Expense / Debt = 4.68% (Interest Expense 595.0m / Debt 12.7b)
Taxrate = 27.80% (1.03b / 3.72b)
NOPAT = 3.18b (EBIT 4.41b * (1 - 27.80%))
Current Ratio = 1.31 (Total Current Assets 15.8b / Total Current Liabilities 12.0b)
Debt / Equity = 0.41 (Debt 12.7b / totalStockholderEquity, last quarter 30.9b)
Debt / EBITDA = 1.65 (Net Debt 10.7b / EBITDA 6.46b)
Debt / FCF = 2.81 (Net Debt 10.7b / FCF TTM 3.80b)
Total Stockholder Equity = 30.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.71% (Net Income 2.68b / Total Assets 57.4b)
RoE = 8.88% (Net Income TTM 2.68b / Total Stockholder Equity 30.1b)
RoCE = 11.59% (EBIT 4.41b / Capital Employed (Equity 30.1b + L.T.Debt 7.94b))
RoIC = 6.98% (NOPAT 3.18b / Invested Capital 45.6b)
WACC = 6.75% (E(62.2b)/V(74.9b) * Re(7.44%) + D(12.7b)/V(74.9b) * Rd(4.68%) * (1-Tc(0.28)))
Discount Rate = 7.44% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 63.96 | Cagr: 0.00%
[DCF] Terminal Value 77.97% ; FCFF base≈3.36b ; Y1≈3.86b ; Y5≈5.68b
[DCF] Fair Price = 294.1 (EV 85.4b - Net Debt 10.7b = Equity 74.7b / Shares 254.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 80.47 | EPS CAGR: 11.61% | SUE: 2.43 | # QB: 1
Revenue Correlation: 76.28 | Revenue CAGR: 4.36% | SUE: 0.11 | # QB: 0
EPS current Quarter (2026-09-30): EPS=3.04 | Chg30d=+19.42% | Revisions=-40% | Analysts=1
EPS current Year (2026-12-31): EPS=12.54 | Chg30d=+7.64% | Revisions=+0% | GrowthEPS=+11.1% | GrowthRev=+0.5%
EPS next Year (2027-12-31): EPS=13.85 | Chg30d=+4.52% | Revisions=+0% | GrowthEPS=+10.5% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: -18% (up=3, down=5)